Fatal Pulmonary Infection due to Multidrug-Resistant Mycobacterium kansasii which Developed in an Immunocompetent Young Man

Internal Medicine

Volumn 36, Issue 4, 1997, Pages 298-300

  Yamada, Hiroshi ^a   Kohyama, Tadashi ^a   Terashi, Kenji ^a   Mori, Hiroyasu ^a   Yamaguchi, Akihiko ^a   Arima, Naomichi ^a   Tanaka, Hiromitsu ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Autopsy; Nontuberculous mycobacteria; Patient's delay

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; CASE REPORT; DRUG EFFECT; FATALITY; HUMAN; IMMUNOCOMPETENCE; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; PROGNOSIS; RESPIRATORY FAILURE; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE; FATAL OUTCOME; HUMANS; IMMUNOCOMPETENCE; MALE; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS, ATYPICAL; PROGNOSIS; RESPIRATORY INSUFFICIENCY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0031114079     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.36.298     Document Type: Article

References (7)

1. Ahn CH, Lowed JR, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 128: 1048, 1983.
2. Research Committee, British Thoracic Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax 49: 442, 1994 (see comments).
3. Johanson WG Jr, Nicholson DP. Pulmonary disease due to Mycobacterium kansasii. An analysis of some factors affecting prognosis. Am Rev Respir Dis 99: 73, 1969.
4. Nakazono T, Sugie T, Ogata H, et al. Investigation on the treatment of infection due to Mycobacterium kansasii. Kekkaku 69: 587, 1994 (Abstract in English).
5. Tsukamura M. Bactericidal activity of ofloxacin against Mycobacterium kansasii. Kekkaku 65: 719, 1990 (Abstract in English).
6. Witzig RS, Franzblau SG. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin and fusidic acid. Antimicrob Agents Chemother 37: 1997, 1993.
7. Ahn CH, Wallace RJ Jr, Steele LC, Murphy DT. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis 135: 10, 1987.